Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

Journal of Medicinal Chemistry

Volumn 59, Issue 12, 2016, Pages 5604-5621

  Castagna, Diana ^a   Budd, David C ^b   MacDonald, Simon J F ^b   Jamieson, Craig ^a   Watson, Allan J B ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; AUTOTAXIN INHIBITOR; GLPG 1690; LYSOPHOSPHATIDIC ACID; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; BENZOXAZOLE DERIVATIVE; BENZOXAZOLONE; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; PHOSPHODIESTERASE;

ANGIOGENESIS; AUTOIMMUNE DISEASE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; FIBROSIS; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NERVE DEGENERATION; NEUROPATHIC PAIN; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

BENZOXAZOLES; BORONIC ACIDS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORIC DIESTER HYDROLASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84976320613     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01599     Document Type: Review

References (107)

1. Albers, H. M. H. G.; Ovaa, H. Chemical evolution of autotaxin inhibitors Chem. Rev. 2012, 112, 2593-2603 10.1021/cr2003213
2. Stefan, C.; Jansen, S.; Bollen, M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases Purinergic Signalling 2006, 2, 361-370 10.1007/s11302-005-5303-4
3. Stracke, M. L.; Krutzsch, H. C.; Unsworth, E. J.; Arestad, A.; Cioce, V.; Schiffmann, E.; Liotta, L. A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein J. Biol. Chem. 1992, 267, 2524-2529
4. Chun, J. Lysophospholipid Receptors Signalling and Biochemistry; John Wiley & Sons Inc, 2013; p 813.
5. Tokumura, A.; Majima, E.; Kariya, Y.; Tominaga, K.; Kogure, K.; Yasuda, K.; Fukuzawa, K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase J. Biol. Chem. 2002, 277, 39436-39442 10.1074/jbc.M205623200
6. Umezu-Goto, M.; Kishi, Y.; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T.; Mills, G. B.; Inoue, K.; Aoki, J.; Arai, H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J. Cell Biol. 2002, 158, 227-233 10.1083/jcb.200204026
7. Akira, T.; Kengo, H.; Kenji, F.; Hiroaki, T. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma Biochim. Biophys. Acta, Lipids Lipid Metab. 1986, 875, 31-38 10.1016/0005-2760(86)90007-X
8. Lin, M. E.; Herr, D. R.; Chun, J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance Prostaglandins Other Lipid Mediators 2010, 91, 130-138 10.1016/j.prostaglandins.2009.02.002
9. Qian, Y.; Hamilton, M.; Sidduri, A.; Gabriel, S.; Ren, Y.; Peng, R.; Kondru, R.; Narayanan, A.; Truitt, T.; Hamid, R.; Chen, Y.; Zhang, L.; Fretland, A. J.; Sanchez, R. A.; Chang, K.-C.; Lucas, M.; Schoenfeld, R. C.; Laine, D.; Fuentes, M. E.; Stevenson, C. S.; Budd, D. C. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts J. Med. Chem. 2012, 55, 7920-7939 10.1021/jm301022v
10. Zhao, Y.; Natarajan, V. Lysophosphatidic acid signaling in airway epithelium: Role in airway inflammation and remodeling Cell. Signalling 2009, 21, 367-377 10.1016/j.cellsig.2008.10.010
11. Mills, G. B.; Moolenaar, W. H. The emerging role of lysophosphatidic acid in cancer Nat. Rev. Cancer 2003, 3, 582-591 10.1038/nrc1143
12. Rivera-Lopez, C.; Tucker, A.; Lynch, K. Lysophosphatidic acid (LPA) and angiogenesis Angiogenesis 2008, 11, 301-310 10.1007/s10456-008-9113-5
13. Bourgion, S. G.; Zhao, C. Autotaxin and lysophospholipids in rheumatoid arthritus Curr. Opin. Invest. Drugs 2010, 11, 515-526
14. Willier, S.; Butt, E.; Grunewald, T. G. P. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: A focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays Biol. Cell 2013, 105, 317-333 10.1111/boc.201300011
15. Tager, A. M.; LaCamera, P.; Shea, B. S.; Campanella, G. S.; Selman, M.; Zhao, Z.; Polosukhin, V.; Wain, J.; Karimi-Shah, B. A.; Kim, N. D.; Hart, W. K.; Pardo, A.; Blackwell, T. S.; Xu, Y.; Chun, J.; Luster, A. D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 2008, 14, 45-54 10.1038/nm1685
16. Zhao, Y.; Natarajan, V. Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2013, 1831, 86-92 10.1016/j.bbalip.2012.06.014
17. Abdel-Magid, A. F. Autotaxin inhibitors may treat pain and osteoarthritis ACS Med. Chem. Lett. 2014, 5, 1072-1073 10.1021/ml5003103
18. Inoue, M.; Rashid, M. H.; Fujita, R.; Contos, J. J. A.; Chun, J.; Ueda, H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling Nat. Med. 2004, 10, 712-714 10.1038/nm1060
19. Benesch, M. G.; Ko, Y. M.; McMullen, T. P.; Brindley, D. N. Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions FEBS Lett. 2014, 588, 2712-2727 10.1016/j.febslet.2014.02.009
20. Giganti, A.; Rodriguez, M.; Fould, B.; Moulharat, N.; Cogé, F.; Chomarat, P.; Galizzi, J.-P.; Valet, P.; Saulnier-Blache, J.-S.; Boutin, J. A.; Ferry, G. Murine and human autotaxin α, β, and γ isoforms: Gene organisation, tissue distribuion, and biochemical characterization J. Biol. Chem. 2008, 283, 7776-7789 10.1074/jbc.M708705200
21. Hausmann, J.; Kamtekar, S.; Christodoulou, E.; Day, J. E.; Wu, T.; Fulkerson, Z.; Albers, H. M. H. G.; van Meeteren, L. A.; Houben, A. J. S.; van Zeijl, L.; Jansen, S.; Andries, M.; Hall, T.; Pegg, L. E.; Benson, T. E.; Kasiem, M.; Harlos, K.; Kooi, C. W. V.; Smyth, S. S.; Ovaa, H.; Bollen, M.; Morris, A. J.; Moolenaar, W. H.; Perrakis, A. Structural basis of substrate discrimination and integrin binding by autotaxin Nat. Struct. Mol. Biol. 2011, 18, 198-204 10.1038/nsmb.1980
22. Nishimasu, H.; Okudaira, S.; Hama, K.; Mihara, E.; Dohmae, N.; Inoue, A.; Ishitani, R.; Takagi, J.; Aoki, J.; Nureki, O. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators Nat. Struct. Mol. Biol. 2011, 18, 205-212 10.1038/nsmb.1998
23. Stein, A. J.; Bain, G.; Prodanovich, P.; Santini, A. M.; Darlington, J.; Stelzer, N. M. P.; Sidhu, R. S.; Schaub, J.; Goulet, L.; Lonergan, D.; Calderon, I.; Evans, J. F.; Hutchinson, J. H. Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding Mol. Pharmacol. 2015, 88, 982-992 10.1124/mol.115.100404
24. Barbayianni, E.; Magrioti, V.; Moutevelis-Minakakis, G. P.; Kokotos, G. Autotaxin inhibitors: A patent review Expert Opin. Ther. Pat. 2013, 23, 1123-1132 10.1517/13543776.2013.796364
25. Gijsbers, R.; Aoki, J.; Arai, H.; Bollen, M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site FEBS Lett. 2003, 538, 60-64 10.1016/S0014-5793(03)00133-9
26. Moolenaar, W. H.; Perrakis, A. Insights into autotaxin: how to produce and present a lipid mediator Nat. Rev. Mol. Cell Biol. 2011, 12, 674-679 10.1038/nrm3188
27. Nishimasu, H.; Ishitani, R.; Aoki, J.; Nureki, O. A 3D view of autotaxin Trends Pharmacol. Sci. 2012, 33, 138-145 10.1016/j.tips.2011.12.004
28. Albers, H. M. H. G.; Hendrickx, L. J. D.; van Tol, R. J. P.; Hausmann, J.; Perrakis, A.; Ovaa, H. Structure-based design of novel boronic acid-based inhibitors of autotaxin J. Med. Chem. 2011, 54, 4619-4626 10.1021/jm200310q
29. Clair, T.; Aoki, J.; Koh, E.; Bandle, R. W.; Nam, S. W.; Ptaszynska, M. M.; Mills, G. B.; Schiffmann, E.; Liotta, L. A.; Stracke, M. L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate Cancer Res. 2003, 63, 5446-5453
30. van Meeteren, L. A.; Ruurs, P.; Christodoulou, E.; Goding, J. W.; Takakusa, H.; Kikuchi, K.; Perrakis, A.; Nagano, T.; Moolenaar, W. H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate J. Biol. Chem. 2005, 280, 21155-21161 10.1074/jbc.M413183200
31. Postma, F. R.; Jalink, K.; Hengevold, T.; Moolenaar, W. H. Sphingosine-1-phosphate rapidly induces Rho-dependant neurite retraction: action through a specific cell surface receptor EMBO J. 1996, 15, 2388-2392
32. Hait, N. C.; Oskeritzian, C. A.; Paugh, S. W.; Milstien, S.; Spiegel, S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases Biochim. Biophys. Acta, Biomembr. 2006, 1758, 2016-2026 10.1016/j.bbamem.2006.08.007
33. Tager, A. M.; LaCamera, P.; Shea, B. S.; Campanella, G. S.; Selman, M.; Zhao, Z.; Polosukhin, V.; Wain, J.; Karimi-Shah, B. A.; Kim, N. D.; Hart, W. K.; Pardo, A.; Blackwell, T. S.; Xu, Y.; Chun, J.; Luster, A. D. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 2008, 14, 45-54 10.1038/nm1685
34. Blanque, R. D. N.; Dupont, S.; Cottereaux, C.; Marsais, F.; Lepescheux, L.; Monjardet, A.; Wakselman, E.; Laenen, W.; Russell, V.; van der Aar, E.; Brys, R.; Heckmann, B. Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment. http://files.glpg.com/docs/website-1/Poster-ERS-2015-final.pdf.
35. Nam, S. W.; Clair, T.; Campo, C. K.; Lee, H. Y.; Liotta, L. A.; Stracke, M. L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metatatic potentil of ras-transformed cells Oncogene 2000, 19, 241-247 10.1038/sj.onc.1203263
36. Yang, Y.; Mou, L. J.; Liu, N.; Tsao, M. S. Autotaxin expression in non-small-cell lung cancer Am. J. Respir. Cell Mol. Biol. 1999, 21, 216-222 10.1165/ajrcmb.21.2.3667
37. Zhang, G.; Zhao, Z.; Xu, S.; Ni, L.; Wang, X. Expression of autotaxin mRNA in human hepatocellular carcinoma Chin. Med. J. (Engl.) 1999, 112, 330-332
38. Stassar, M. J. J. G.; Devitt, G.; Brosius, M.; Rinnab, L.; Prang, J.; Schradin, T.; Simon, J.; Petersen, S.; Kopp-Schneider, A.; Zöller, M. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization Br. J. Cancer 2001, 85, 1372-1382 10.1054/bjoc.2001.2074
39. Yang, S.; Lee, J.; Park, C.; Kim, S.; Hong, S.; Chung, H.; Min, S.; Han, J.; Lee, H.; Lee, H. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells Clin. Exp. Metastasis 2002, 19, 603-608 10.1023/A:1020950420196
40. Panupinthu, N.; Lee, H. Y.; Mills, G. B. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression Br. J. Cancer 2010, 102, 941-946 10.1038/sj.bjc.6605588
41. Kehlen, A.; Englert, N.; Seifert, A.; Klonisch, T.; Dralle, H.; Langner, J.; Hoang-Vu, C. Expression, regulation and function of autotaxin in thyroid carcinomas Int. J. Cancer 2004, 109, 833-838 10.1002/ijc.20022
42. Barbayianni, E.; Kaffe, E.; Aidinis, V.; Kokotos, G. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer Prog. Lipid Res. 2015, 58, 76-96 10.1016/j.plipres.2015.02.001
43. Lee, S. C.; Fukiwara, Y.; Tigyi, G. J. Uncovering unique roles of LPA receptors in tumor microenviroment Recept. Clin. Invest. 2015, 2, e440
44. Nakagawa, H.; Ikeda, H.; Nakamura, K.; Ohkawa, R.; Masuzaki, R.; Tateishi, R.; Yoshida, H.; Watanabe, N.; Tejima, K.; Kume, Y.; Iwai, T.; Suzuki, A.; Tomiya, T.; Inoue, Y.; Nishikawa, T.; Ohtomo, N.; Tanoue, Y.; Omata, M.; Igarashi, K.; Aoki, J.; Koike, K.; Yatomi, Y. Autotaxin as a novel serum marker of liver fibrosis Clin. Chim. Acta 2011, 412, 1201-1206 10.1016/j.cca.2011.03.014
45. 1 receptor activation promotes renal interstitial fibrosis J. Am. Soc. Nephrol. 2007, 18, 3110-3118 10.1681/ASN.2007020196
46. Rancoule, C.; Viaud, M.; Gres, S.; Viguerie, N.; Decaunes, P.; Bouloumié, A.; Langin, D.; Bascands, J.-L.; Valet, P.; Saulnier-Blache, J. S. Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: In vivo and in vitro evidence Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2014, 1841, 88-96 10.1016/j.bbalip.2013.10.003
47. Wu, L.; Petrigliano, F. A.; Ba, K.; Lee, S.; Bogdanov, J.; McAllister, D. R.; Adams, J. S.; Rosenthal, A. K.; Van Handel, B.; Crooks, G. M.; Lin, Y.; Evseenko, D. Lysophosphatidic acid mediates fibrosis in injured joints by regulating collagen type I biosynthesis Osteoarthr. Cartil. 2015, 23, 308-318 10.1016/j.joca.2014.11.012
48. Abu El-Asrar, A.; Mohammad, G.; Nawaz, M.; Siddiquei, M.; Kangave, D.; Opdenakker, G. Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy Acta Diabetol. 2013, 50, 363-371 10.1007/s00592-012-0422-1
49. Tager, A. M. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 2012, 47, 563-565 10.1165/rcmb.2012-0235ED
50. Oikonomou, N.; Mouratis, M.-A.; Tzouvelekis, A.; Kaffe, E.; Valavanis, C.; Vilaras, G.; Karameris, A.; Prestwich, G. D.; Bouros, D.; Aidinis, V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 2012, 47, 566-574 10.1165/rcmb.2012-0004OC
51. Montesi, S.; Mathai, S.; Brenner, L.; Gorshkova, I.; Berdyshev, E.; Tager, A.; Shea, B. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis BMC Pulm. Med. 2014, 14, 5 10.1186/1471-2466-14-5
52. Funke, M.; Zhao, Z.; Xu, Y.; Chun, J.; Tager, A. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury Am. J. Respir. Cell Mol. Biol. 2012, 46, 355-364 10.1165/rcmb.2010-0155OC
53. Huang, L.; Fu, P.; Patel, P.; Harijith, A.; Sun, T.; Zhao, Y.; Garcia, J.; Chun, J.; Natarajan, V. Lysophosphatidic acid receptor 2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice Am. J. Respir. Cell Mol. Biol. 2013, 49, 912-922 10.1165/rcmb.2013-0070OC
54. 3 antagonist on experimental murine scleroderma induced by bleomycin Experimental Dermatology 2015, 24, 698-702 10.1111/exd.12752
55. Jiang, G.; Madan, D.; Prestwich, G. D. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin Bioorg. Med. Chem. Lett. 2011, 21, 5098-5101 10.1016/j.bmcl.2011.03.068
56. Umemura, K.; Yamashita, N.; Yu, X.; Arima, K.; Asada, T.; Makifuchi, T.; Murayama, S.; Saito, Y.; Kanamaru, K.; Goto, Y.; Kohsaka, S.; Kanazawa, I.; Kimura, H. Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients Neurosci. Lett. 2006, 400, 97-100 10.1016/j.neulet.2006.02.008
57. Hammack, B. N.; Fung, K. Y.; Hunsucker, S. W.; Duncan, M. W.; Burgoon, M. P.; Owens, G. P.; Gilden, D. H. Proteomic analysis of multiple sclerosis cerebrospinal fluid Multiple Sclerosis 2004, 10, 245-260 10.1191/1352458504ms1023oa
58. Inoue, M.; Ma, L.; Aoki, J.; Chun, J.; Ueda, H. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain Mol. Pain 2008, 4, 6 10.1186/1744-8069-4-6
59. Gududuru, V.; Zeng, K.; Tsukahara, R.; Makarova, N.; Fujiwara, Y.; Pigg, K. R.; Baker, D. L.; Tigyi, G.; Miller, D. D. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors Bioorg. Med. Chem. Lett. 2006, 16, 451-456 10.1016/j.bmcl.2005.08.096
60. Gierse, J.; Thorarensen, A.; Beltey, K.; Bradshaw-Pierce, E.; Cortes-Burgos, L.; Hall, T.; Johnston, A.; Murphy, M.; Nemirovskiy, O.; Ogawa, S.; Pegg, L.; Pelc, M.; Prinsen, M.; Schnute, M.; Wendling, J.; Wene, S.; Weinberg, R.; Wittwer, A.; Zweifel, B.; Masferrer, J. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation J. Pharmacol. Exp. Ther. 2010, 334, 310-317 10.1124/jpet.110.165845
61. Hoeglund, A. B.; Howard, A. L.; Wanjala, I. W.; Pham, T. C. T.; Parrill, A. L.; Baker, D. L. Characterization of non-lipid autotaxin inhibitors Bioorg. Med. Chem. 2010, 18, 769-776 10.1016/j.bmc.2009.11.056
62. Fells, J. I.; Lee, S. C.; Fujiwara, Y.; Norman, D. D.; Lim, K. G.; Tsukahara, R.; Liu, J.; Patil, R.; Miller, D. D.; Kirby, R. J.; Nelson, S.; Seibel, W.; Papoian, R.; Parrill, A. L.; Baker, D. L.; Bittman, R.; Tigyi, G. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface Mol. Pharmacol. 2013, 84, 415-424 10.1124/mol.113.087080
63. Albers, H. M. H. G.; van Meeteren, L. A.; Egan, D. A.; van Tilburg, E. W.; Moolenaar, W. H.; Ovaa, H. Discovery and optimization of boronic acid based inhibitors of autotaxin J. Med. Chem. 2010, 53, 4958-4967 10.1021/jm1005012
64. Fells, J. I.; Lee, S. C.; Norman, D. D.; Tsukahara, R.; Kirby, J. R.; Nelson, S.; Seibel, W.; Papoian, R.; Patil, R.; Miller, D. D.; Parrill, A. L.; Pham, T.-C.; Baker, D. L.; Bittman, R.; Tigyi, G. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif FEBS J. 2014, 281, 1017-1028 10.1111/febs.12674
65. Takakusa, H.; Kikuchi, K.; Urano, Y.; Sakamoto, S.; Yamaguchi, K.; Nagano, T. Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer J. Am. Chem. Soc. 2002, 124, 1653-1657 10.1021/ja011251q
66. North, E. J.; Howard, A. L.; Wanjala, I. W.; Pham, T. C. T.; Baker, D. L.; Parrill, A. L. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors J. Med. Chem. 2010, 53, 3095-3105 10.1021/jm901718z
67. Ferguson, C. G.; Bigman, C. S.; Richardson, R. D.; van Meeteren, L. A.; Moolenaar, W. H.; Prestwich, G. D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity Org. Lett. 2006, 8, 2023-2026 10.1021/ol060414i
68. Morris, A. J.; Smyth, S. S. Measurement of autotaxin/lysophospholipase D activity Methods Enzymol. 2007, 434, 89-104 10.1016/S0076-6879(07)34005-6
69. Fells, J. I.; Lee, S. C.; Norman, D. D.; Tsukahara, R.; Kirby, R. J.; Nelson, S.; Seibel, W.; Papoian, R.; Patil, R.; Miller, D. D.; Parrill, A. L.; Pham, T. C.; Baker, D. L.; Bittman, R.; Tigyi, G. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif FEBS J. 2014, 281, 1017-1028 10.1111/febs.12674
70. Miller, D. D.; Tigyi, G. J.; Gududuru, V.; Fujiwara, Y.; Baker, D.; Walker, M. D.; Durgam, G. G. Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors. U.S. Pat. Appl. 2006/0270634 A1, 2006.
71. Tsuda, S.; Okudaira, S.; Moriya-Ito, K.; Shimamoto, C.; Tanaka, M.; Aoki, J.; Arai, H.; Murakami-Murofushi, K.; Kobayashi, T. Cyclic phosphatidic acid is produced by autotaxin in blood J. Biol. Chem. 2006, 281, 26081-26088 10.1074/jbc.M602925200
72. Kazius, J.; McGuire, R.; Bursi, R. Derivation and validation of toxicophores for mutagenicity prediction J. Med. Chem. 2005, 48, 312-320 10.1021/jm040835a
73. Prestwich, G.; Tigyi, G.; Jiang, G.; Zhang, G.; Gajwiak, J.; Zhang, H.; Xu, X. α-Chloro and α-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using hereof. PCT Int. Appl. WO 2008/157361 A1, 2008.
74. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
75. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 10.1021/jm701122q
76. Murph, M. M.; Jiang, G. W.; Altman, M. K.; Jia, W.; Nguyen, D. T.; Fambrough, J. M.; Hardman, W. J.; Nguyen, H. T.; Tran, S. K.; Alshamrani, A. A.; Madan, D.; Zhang, J.; Prestwich, G. D. Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma Bioorg. Med. Chem. 2015, 23, 5999-6013 10.1016/j.bmc.2015.06.054
77. Schiemann, K.; Schultz, M.; Staehle, W. Piperidine and piperazine derivatives as autotaxin inhibitors. U.S. Pat. Appl. 2014/0343075 A1, 2014.
78. Legrand, D. M.; Furminger, V.; Thomson, C.; Hughes, O. R.; Stanley, E. Autotaxin inhibitors. U.S. Pat. Appl. 2014/0171403 A1, 2014.
79. Staehle, W.; Schiemann, K.; Schultz, M. Heterocyclic compounds as autotaxin inhibitors. U.S. Pat. Appl. 2012/0015959 A1, 2010.
80. Roppe, J. R.; Parr, T. A.; Hutchinson, J. H. Heterocyclic autotaxin inhibitors and uses therof. U.S. Pat. Appl. 2013/0029948 A1, 2013.
81. Roppe, J. F.; Parr, T. A.; Stock, S. T.; Volkots, D.; Hutchinson, J. H. Autotaxin inhibitors and uses therof. PCT Int. Appl. WO2012/024620 A2, 2012.
82. Hutchinson, J. H.; Parr, T. A.; Bunker, K. D.; Lonergan, D. Vinyl autotaxin inhibitor compounds. PCT Int. Appl. WO2015/042053 A1, 2015.
83. Hutchinson, J. H.; Lonergan, D. Tetracyclic autotaxin inhibitors. PCT Int. Appl. WO2015/077502 A1, 2015.
84. Hutchinson, J. H.; Parr, T. A.; Bunker, K. D.; Lonergan, D. Heterocyclic vinyl autotaxin inhibitor compounds. PCT Int. Appl. WO2015/042052 A1, 2015.
85. Hutchinson, J. H.; Lonergan, D.; Huang, F.; Rowbottom, M.; Calderon, I. Autotaxin inhibitor compounds. PCT Int. Appl. WO2015/048301 A1, 2015.
86. Hutchinson, J. E.; Lonegan, D. Autotaxin inhibitor compounds. PCT Int. Appl. WO2015/077503 A1, 2015.
87. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
88. Hert, J.; Hunziker, D.; Mattel, P.; Mauser, H.; Tang, G.; Wang, L. New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogues thereof as autotaxin inhibitors. PCT Int. Appl. WO2014/139978 A1, 2014.
89. Hert, J.; Hunziker, D.; Mattel, P.; Mauser, H.; Tang, G.; Wang, L. New bicycle derivatives. PCT Int. Appl. WO2014/048865 A1, 2014.
90. Jones, S. B.; Norman, B. H.; Pfeifer, L. A. Imidazo pyridine compounds. PCT Int. Appl. WO2014143583 A1, 2014.
91. Bleisch, T. J.; Doti, R. A.; Pfeifer, L. A.; Norman, B. H. Dihydropyrido pyrimidine compounds as autotaxin inhibitors. PCT Int. Appl. WO2014/168824 A1, 2014.
92. Beauchamp, T. J.; Dao, Y.; Jones, S. B.; Norman, B. H.; Pfeifer, L. A. Bicycle pyrimidine compounds. U.S. Pat. Appl. 2014/0200231 A1, 2014.
93. Hansen, M. M.; Jolly, R. A.; Linder, R. J. Boronic acids and derivatives-probing the structure-activity relationships for mutagenicity Org. Process Res. Dev. 2015, 19, 1507-1516 10.1021/acs.oprd.5b00150
94. Castagna, D.; Duffy, E. L.; Semaan, D.; Young, L. C.; Pritchard, J. M.; Macdonald, S. J. F.; Budd, D. C.; Jamieson, C.; Watson, A. J. B. Identification of a novel class of autotaxin inhibitors through cross-screening MedChemComm 2015, 6, 1149-1155 10.1039/C5MD00081E
95. Desroy, N.; Heckmann, B.; Brys, R. C. X.; Joncour, A. M.; Peioxoto, C.; Bock, X. M. Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. PCT Int. Appl. WO2014/202458 A1, 2014.
96. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
97. JChem for Excel 6.0; ChemAxon, 2013.
98. van der Aar, E.; Fagard, L.; Desrivot, J.; Dupont, S.; Heckmann, B.; Blanque, R.; Gheyle, L.; Ralic, J.; Vanhoutte, F. Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Eur. Respir. J. 2015, 46, OA484 10.1183/13993003.congress-2015.OA484
99. Lynch, K. R.; MacDonald, T. L. Phosphonate derivatives as autotaxin inhibitors. U.S. Pat. Appl. 2010/0016258 A1, 2010.
100. Gupte, R.; Miller, D. D.; Patil, R.; Tigyi, G. Inhibitors of autotaxin. PCT Int. Appl. WO2012100018 A1, 2010.
101. St-Cœur, P.-D.; Ferguson, D.; Morin, P., Jr.; Touaibia, M. PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability Arch. Pharm. 2013, 346, 91-97 10.1002/ardp.201200395
102. Schiemann, K.; Schultz, M.; Blaukat, A.; Kober, I. Piperidine and piperazine derivatives for treating tumours. PCT Int. Appl. WO2009046841 A8, 2010.
103. Schiemann, K.; Schultz, M.; Staehle, W. Piperidine and piperazine derivatives as autotaxin inhibitors. PCT Int. Appl. WO 2010115491 A2, 2010.
104. Baettig, U.; Beattie, D.; Legrand, M. D.; Lister, A. S.; Mckenna, J.; Pearce, D. W.; Sandham, D. A.; Stanley, E. Autotaxin inhibitors. PCT Int. Appl. WO2015/008229 A1, 2015.
105. Furminger, V.; Hughes, O. R.; Legrand, D. M.; Stanley, E.; Thomson, C. Autotaxin inhibitors. U.S. Pat. Appl. 2014/0171404 A1, 2014.
106. Long, S. A.; Thorarensen, A.; Schnute, M. E. Pyrimidine and pyridine derivatives useful in therapy. PCT Int. Appl. WO2013054185 A1, 2013.
107. Parrill-Baker, A. L.; Baker, D. L. Autotaxin inhibitors. U.S. Pat. Appl. 8,969,590 B1, 2015.